CARLSBAD, Calif., May 12, 2016 /PRNewswire/ -- ArtVentive Medical Group, Inc. commenced the launch of its flagship occlusion device product, the ArtVentive Endoluminal Occlusion System (EOS™) at the Global Embolization Symposium and Technologies (GEST) in New York, NY on May 5-8. The introduction in the United States follows the initial commercialization in the E.U. last year.
Dr. Jafar Golzarian, MD, GEST co-founder and Director of Interventional Radiology and Vascular Imaging at the University of Minnesota presented the ArtVentive EOS™ device to a standing room only audience of over 200 vascular surgeons and interventional radiologists in a session titled the "New World of Micro Plugs."
Dr. Marc Sapoval, GEST co-chairman and Professor of Clinical Radiology and Chair of the Cardiovascular Radiology Department Georges Pompidou Hospital, Paris, France deployed the device during the demonstration at the "Master class and Materials: Coils and Plugs".
Dr. Adriaan Moelker, MD, PhD, Head Section Interventional Radiology at the Department of Radiology, Erasmus University Medical Center in Rotterdam, the largest interventional radiology practice in the Netherlands, described his experience as an early adapter of EOS™. His pioneering usage of the vascular occlusion device was demonstrated in multiple case studies conducted at his hospital and he reported his clinical experience and resultant benefits of using the ArtVentive EOS™ device in multiple arterial and venous applications.
Dr. Moelker explained that he and his team "repeatedly used ArtVentive EOS™ at Erasmus University Medical Center in our practice of embolization procedures. The ArtVentive EOS™ device has a unique ability to act immediately, instantly occluding targeted vessels. EOS™ reduces procedure time substantially compared to conventional coil insertion, decreasing the amount of radiation received by both medical personnel and patient. EOS™ has great impact on our everyday practice, significantly reducing expenses and the negative effects of use of radiation during the procedure."
Leon Rudakov, PhD, President and Chief Technology Officer of ArtVentive, commented, "This year, ArtVentive has established two Centers in the United States at George Washington University and TUFTS with interventional radiologists that are committed to assisting us in introducing our product to other professionals and hospitals. EOS™ is CE-marked and recently received FDA 510(k) approval in Q4 2015 and we are now strategically expanding our European and US operations through selecting distributors and proctoring centers."
"GEST 2016 provided an ideal platform for us to launch our U.S. commercialization efforts with our exposure to the top professionals in the world and the opportunity to proctor over 50 physicians with hands-on training on the use of EOS™. ArtVentive demonstrated how EOS™ provides immediate and permanent occlusion, with key competitive advantages and clinical benefits over traditional methods and devices. We are off to a great start in 2016 and look forward to continuing our product launch in the U.S. and expanding our EOS™ technology platform beyond peripheral vascular to other critical treatments in the rapidly growing field of interventional radiology, vascular surgery and beyond."
About ArtVentiveMedical Group, Inc.
ArtVentive Medical Group, Inc., with corporate headquarters in Carlsbad, California, is an innovative, multi-faceted medical device company focused on developing, manufacturing and marketing globally a family of devices featuring the ArtVentive EOS™.
The ArtVentive EOS™ is a catheterbased, selfexpandable device, which facilitates permanent and immediate occlusion of peripheral vessels. The ArtVentive EOS™ is designed to serve as a safe and reliable alternative to major surgery in certain cases.
This news release contains "forwardlooking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forwardlooking statements relate to the Company's current expectations, projections and beliefs concerning matters that are not historical facts. Forwardlooking statements are not guarantees of future performance. Forwardlooking statements involve uncertainties, risks, assumptions and contingencies, many of which are outside the Company's control, and, thus, actual results could differ materially from those described in or implied by any forwardlooking statement. All forwardlooking statements are based on currently available information and speak only as of the date on which they are made. The Company assumes no obligation to update any forwardlooking statement made in this news release that becomes untrue because of subsequent events, new information or otherwise, except to the extent it is required to do so in connection with the Company's ongoing requirements under federal securities laws. For a further discussion of factors that could cause the Company's future results to differ materially from any forwardlooking statements, see the Company's Annual Report on Form 10K for the fiscal year ended December 31, 2015 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission.
For More Information please visit our website:
Contact: Leon Rudakov
This content was issued through the press release distribution service at Newswire.com. For more info visit: http://www.newswire.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/artventive-launches-us-commercialization-300267814.html
SOURCE ArtVentive Medical Group, Inc.